Aulos Bioscience, Inc.

Two companies with different approaches to RNA medicines announced venture capital mega-rounds of $100m or more on 9 August – ADARx Pharmaceuticals, Inc. with a $200m series C financing and Alltrna

Adding patient-reported outcomes data to clinician-reported adverse events in early cancer drug trials could better inform dose selection and optimization, US Food and Drug Administration officials sa

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Biolojic To Use Computational Platform